Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 72 post-ruxolitinib window

Composite Biomarkers

Post-HSCT Monitoring - 30.1 months

Generated 2026-05-28 07:28 · Post-HSCT Patient

ADSI

Elevated

66.2/100

Autonomic Dysfunction | worsening (30-day trend)

Autonomic Dysfunction Severity Index. Higher = more dysfunction.

GVHD Score

Normal

33.8/100

Wearable Activity | worsening (30-day trend)

Composite from HRV, HR, sleep fragmentation, temperature. Ring-derived, not clinical diagnosis.

Recovery

Normal

91.7/100

Trajectory Index | worsening (30-day trend)

Overall recovery trajectory. Higher = better.

Pharma

Info

2.8Z

Ruxolitinib Response | stable (30-day trend)

Pharmacodynamic response to ruxolitinib. Z-score relative to pre-treatment baseline.

CV Risk

Elevated

53.3/100

Cardiovascular Composite | stable (30-day trend)

Cardiovascular risk proxy from resting HR, HRV, SpO2. Not equivalent to Framingham or SCORE2.

Allostatic

Normal

1.0/7

Load Score | stable (30-day trend)

Cumulative physiological stress burden. Scale 0-7.

Summary

Post-HSCT Patient | 30.1 months post-HSCT | Ruxolitinib from 2026-03-16

Biomarker	Value	Trend
ADSI	66.2/100	worsening (30-day trend)
GVHD_SCORE	33.8/100	worsening (30-day trend)
RECOVERY_INDEX	91.7/100	worsening (30-day trend)
CV_RISK	53.3/100	stable (30-day trend)
ALLOSTATIC_LOAD	1.0/7	stable (30-day trend)

HRV (RMSSD)

Significant

145.8% change

p=0.0000, d=1.65 (large)

Lowest HR

Significant

-14.7% change

p=0.0000, d=1.56 (large)

Average HR

Significant

-12.7% change

p=0.0000, d=1.50 (large)

Sleep Efficiency

Significant

4.3% change

p=0.0000, d=0.81 (large)

Metric	Pre-Rux (mean±SD)	Post-Rux (mean±SD)	Change	Cohen's d	Effect
HRV (RMSSD)	10.0 ± 2.5 ms	24.5 ± 12.0 ms	+145.8%	1.65	large
Lowest HR	76.7 ± 5.7 bpm	65.4 ± 8.4 bpm	-14.7%	1.56	large
Average HR	85.2 ± 6.8 bpm	74.3 ± 7.6 bpm	-12.7%	1.50	large
Sleep Efficiency	78.6 ± 3.4 %	82.0 ± 4.9 %	+4.3%	0.81	large

Three-Period Trajectory

Pre-acute (2026-02-09) → Post-acute/Pre-Rux → Post-Rux (2026-03-16)

HRV (RMSSD): 8.6 ms → 11.2 ms → 24.5 ms (acute event = inflection, Rux stabilized)

Lowest HR: 79.6 bpm → 74.1 bpm → 65.4 bpm (steady improvement)

Average HR: 88.7 bpm → 82.0 bpm → 74.3 bpm (steady improvement)

Sleep Efficiency: 78.1 % → 79.1 % → 82.0 %

Clinical note: The composite ADSI score dilutes these individual metric signals. While ADSI aggregates multiple domains into a single index, individual metrics like HRV and heart rate show statistically significant pre/post differences that the composite score may obscure through averaging.

Biomarker Dashboard

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – May 26, 2026 · Post-intervention: 72 days (ruxolitinib, March 16)